Association between surgical volume and post-operative mortality and survival after surgical resection in lung cancer in Belgium: A population-based study
ConclusionIn Belgium, a higher hospital surgical volume is associated with improved outcome in NSCLC patients after surgical resection. Minimally 10 surgical interventions per year seem to be required to achieve an optimal performance.
Comparative studies of the overall survival (OS) in elderly patients with nonsmall cell lung cancer (NSCLC) after surgery or stereotactic body radiotherapy (SBRT) have been limited by mixed extents of resection and different surgical approaches. 792 patients aged ≥65 years with clinical stage I NSCLC underwent video-assisted thoracic surgery (VATS) lobectomy or SBRT between 2010 and 2015. The propensity score-matched primary analysis included data from the full cohort; the secondary analysis included data from a subgroup of patients with data on pulmonary function. Median OS for unmatched patients was 77 month...
Currently, the standard of care for resectable, early-stage and functionally operable nonsmall cell lung cancer (NSCLC) is complete surgical resection . However, for elderly patients and patients with multiple comorbidities, surgery may not be the preferred option due to higher surgical morbidity and mortality . An alternative treatment for this group of patients is stereotactic body radiotherapy (SBRT), which administers a high local dose of radiation in fewer fractions as an ablative treatment . In recent years, SBRT has gained in popularity as it has shown better local control rates and less toxicity to surroun...
In patients with locally advanced non-small-cell lung cancer undergoing radiotherapy, cardiac radiation exposure is an independent predictor of adverse outcomes, according to a retrospective analysis.Reuters Health Information
Condition: Non-small Cell Carcinoma Interventions: Drug: Binimetinib; Drug: Pembrolizumab Sponsor: University Health Network, Toronto Not yet recruiting
Publication date: Available online 19 June 2019Source: Pharmacology &TherapeuticsAuthor(s): Michela Terlizzi, Chiara Colarusso, Aldo Pinto, Rosalinda SorrentinoAbstractThe discovery of genetic alterations, that can be targeted therapeutically, has launched a new era for lung cancer research and personalized therapy. However, not all the identified new genetic driver mutations are therapeutically targetable due to high toxicity profile. On the other hand, those genetic alterations that could be pharmacologically targeted, are often subject of alternative mutations that lead to drug resistance, which represents one of th...
In conclusion, the results demonstrated that BD exerted anti-cancer activity against NSCLC cells through JNK activation, which suggests its potent usefulness for prevention and treatment of NSCLC.Graphical abstract
Conclusions: IO patients showed significant benefit in OS with HRs comparable to those reported in phase III trials. The benefit tended to be greater in patients with lower tumor mass.Oncology
Recent clinical trials have put immunotherapy front and center for initial treatment decisions in advanced lung cancer.Journal of Clinical Oncology
First major improvements in NSCLC care have been achieved by the identification of targetable oncogenic alterations together with specific targeted therapies. However, the vast majority of Caucasian lung cancer patients do not present with a targetable driver mutation and standard cytotoxic chemotherapy (ChT) and anti-angiogenic strategies represented the cornerstones of systemic lung cancer treatment for decades. Nowadays, the treatment of advanced Non-Small-Cell Lung Cancer (NSCLC) is radically transforming.